Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammaplasty | 20 | 2023 | 107 | 8.950 |
Why?
|
| Adipose Tissue | 19 | 2022 | 241 | 6.440 |
Why?
|
| Breast Neoplasms | 23 | 2023 | 2904 | 3.340 |
Why?
|
| Transplantation, Autologous | 15 | 2022 | 331 | 2.550 |
Why?
|
| Mastectomy, Segmental | 5 | 2023 | 93 | 2.050 |
Why?
|
| Breast Implants | 5 | 2020 | 23 | 1.960 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 5 | 2013 | 53 | 1.600 |
Why?
|
| Adipocytes | 3 | 2022 | 154 | 1.590 |
Why?
|
| Venous Thrombosis | 3 | 2018 | 243 | 1.550 |
Why?
|
| Lymphedema | 2 | 2022 | 77 | 1.480 |
Why?
|
| Mastectomy | 11 | 2023 | 243 | 1.400 |
Why?
|
| Breast | 9 | 2022 | 288 | 1.390 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 4 | 2020 | 8 | 1.360 |
Why?
|
| Anastomosis, Surgical | 3 | 2018 | 267 | 1.310 |
Why?
|
| Free Tissue Flaps | 4 | 2021 | 49 | 0.970 |
Why?
|
| Tissue and Organ Harvesting | 3 | 2021 | 79 | 0.960 |
Why?
|
| Tissue Scaffolds | 3 | 2014 | 106 | 0.930 |
Why?
|
| Fat Necrosis | 1 | 2022 | 6 | 0.870 |
Why?
|
| Humans | 57 | 2023 | 85778 | 0.840 |
Why?
|
| Postoperative Complications | 7 | 2022 | 2202 | 0.840 |
Why?
|
| Microsurgery | 4 | 2022 | 84 | 0.830 |
Why?
|
| Tissue Engineering | 5 | 2021 | 181 | 0.780 |
Why?
|
| Wound Healing | 3 | 2013 | 345 | 0.760 |
Why?
|
| Ki-1 Antigen | 1 | 2020 | 17 | 0.730 |
Why?
|
| Lipectomy | 1 | 2019 | 9 | 0.680 |
Why?
|
| Female | 34 | 2023 | 44216 | 0.670 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 378 | 0.670 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 342 | 0.660 |
Why?
|
| Acellular Dermis | 1 | 2018 | 4 | 0.650 |
Why?
|
| Breast Implantation | 1 | 2018 | 12 | 0.640 |
Why?
|
| Tissue Expansion | 1 | 2018 | 19 | 0.640 |
Why?
|
| Mass Screening | 1 | 2022 | 601 | 0.620 |
Why?
|
| Macrophages | 4 | 2013 | 560 | 0.580 |
Why?
|
| Immunophenotyping | 3 | 2013 | 211 | 0.580 |
Why?
|
| Abdominal Fat | 2 | 2013 | 13 | 0.580 |
Why?
|
| Middle Aged | 18 | 2022 | 24740 | 0.540 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 2 | 2013 | 31 | 0.510 |
Why?
|
| Bone Marrow Cells | 2 | 2013 | 253 | 0.510 |
Why?
|
| Hyaluronic Acid | 2 | 2013 | 48 | 0.500 |
Why?
|
| Prospective Studies | 8 | 2022 | 4160 | 0.490 |
Why?
|
| Immunomodulation | 1 | 2014 | 55 | 0.490 |
Why?
|
| Skin | 3 | 2019 | 554 | 0.460 |
Why?
|
| Retrospective Studies | 14 | 2022 | 8456 | 0.450 |
Why?
|
| Biocompatible Materials | 1 | 2014 | 193 | 0.440 |
Why?
|
| Perforator Flap | 2 | 2022 | 12 | 0.420 |
Why?
|
| Autografts | 3 | 2021 | 28 | 0.420 |
Why?
|
| Cell Lineage | 1 | 2013 | 280 | 0.420 |
Why?
|
| Adult | 18 | 2021 | 25518 | 0.420 |
Why?
|
| Aged | 14 | 2021 | 18161 | 0.390 |
Why?
|
| Tracheal Diseases | 1 | 2010 | 13 | 0.380 |
Why?
|
| Laryngeal Diseases | 1 | 2010 | 20 | 0.370 |
Why?
|
| Filtration | 2 | 2021 | 25 | 0.370 |
Why?
|
| Time and Motion Studies | 2 | 2021 | 21 | 0.370 |
Why?
|
| Vocal Cords | 1 | 2010 | 25 | 0.360 |
Why?
|
| Propensity Score | 2 | 2021 | 132 | 0.350 |
Why?
|
| Seroma | 2 | 2020 | 6 | 0.350 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 3591 | 0.330 |
Why?
|
| Skin Diseases | 1 | 2010 | 165 | 0.320 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 232 | 0.290 |
Why?
|
| Surgery, Plastic | 2 | 2021 | 42 | 0.290 |
Why?
|
| Fibroblasts | 1 | 2010 | 731 | 0.290 |
Why?
|
| Flow Cytometry | 4 | 2013 | 680 | 0.290 |
Why?
|
| Time Factors | 6 | 2020 | 5178 | 0.280 |
Why?
|
| Head and Neck Neoplasms | 3 | 2019 | 1052 | 0.270 |
Why?
|
| Neoplasms | 1 | 2021 | 2895 | 0.270 |
Why?
|
| Coculture Techniques | 4 | 2013 | 164 | 0.260 |
Why?
|
| Cells, Cultured | 6 | 2013 | 2836 | 0.260 |
Why?
|
| Patient Preference | 2 | 2023 | 104 | 0.250 |
Why?
|
| Young Adult | 6 | 2021 | 5961 | 0.240 |
Why?
|
| Cell Differentiation | 5 | 2013 | 1471 | 0.230 |
Why?
|
| Treatment Outcome | 5 | 2022 | 7830 | 0.220 |
Why?
|
| Trauma Centers | 2 | 2015 | 115 | 0.220 |
Why?
|
| Mammary Arteries | 1 | 2022 | 31 | 0.210 |
Why?
|
| Shoulder | 1 | 2022 | 40 | 0.210 |
Why?
|
| Myocutaneous Flap | 1 | 2021 | 5 | 0.200 |
Why?
|
| Arm | 1 | 2022 | 91 | 0.200 |
Why?
|
| Community Participation | 1 | 2021 | 36 | 0.200 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 454 | 0.200 |
Why?
|
| Embolism, Fat | 1 | 2021 | 2 | 0.200 |
Why?
|
| Centrifugation | 1 | 2021 | 24 | 0.200 |
Why?
|
| Drainage | 1 | 2022 | 157 | 0.200 |
Why?
|
| Lymphangiogenesis | 1 | 2021 | 39 | 0.190 |
Why?
|
| Clothing | 1 | 2020 | 6 | 0.190 |
Why?
|
| Rectus Abdominis | 2 | 2010 | 37 | 0.180 |
Why?
|
| Physicians, Women | 1 | 2020 | 53 | 0.180 |
Why?
|
| Cadaver | 2 | 2018 | 184 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 6479 | 0.180 |
Why?
|
| Quality of Life | 3 | 2022 | 1581 | 0.180 |
Why?
|
| Nipples | 1 | 2019 | 37 | 0.170 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 38 | 0.170 |
Why?
|
| Skin Transplantation | 2 | 2010 | 172 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 98 | 0.170 |
Why?
|
| Subcutaneous Fat | 1 | 2018 | 18 | 0.160 |
Why?
|
| Freeze Drying | 1 | 2018 | 14 | 0.160 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 37 | 0.160 |
Why?
|
| Operating Rooms | 1 | 2019 | 126 | 0.160 |
Why?
|
| Surgical Flaps | 2 | 2010 | 241 | 0.160 |
Why?
|
| Endothelial Cells | 1 | 2021 | 443 | 0.160 |
Why?
|
| Graft Survival | 2 | 2021 | 885 | 0.160 |
Why?
|
| Education, Medical | 1 | 2020 | 234 | 0.150 |
Why?
|
| Treatment Failure | 1 | 2018 | 283 | 0.150 |
Why?
|
| Microvessels | 1 | 2017 | 69 | 0.150 |
Why?
|
| Epinephrine | 1 | 2017 | 84 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 500 | 0.150 |
Why?
|
| Lidocaine | 1 | 2017 | 63 | 0.150 |
Why?
|
| Suture Techniques | 1 | 2017 | 134 | 0.140 |
Why?
|
| Anesthetics, Local | 1 | 2017 | 76 | 0.140 |
Why?
|
| Surgeons | 1 | 2020 | 233 | 0.140 |
Why?
|
| Esthetics | 2 | 2020 | 44 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 182 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2019 | 832 | 0.140 |
Why?
|
| Mammography | 1 | 2019 | 463 | 0.140 |
Why?
|
| Male | 9 | 2021 | 40652 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2019 | 329 | 0.130 |
Why?
|
| Students, Medical | 1 | 2020 | 386 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2019 | 426 | 0.130 |
Why?
|
| Facial Injuries | 1 | 2015 | 19 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2702 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 240 | 0.130 |
Why?
|
| Foreign-Body Reaction | 1 | 2014 | 11 | 0.120 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2015 | 91 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1313 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 292 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2014 | 156 | 0.120 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2013 | 16 | 0.120 |
Why?
|
| Gelatin | 1 | 2013 | 25 | 0.120 |
Why?
|
| Reoperation | 2 | 2019 | 593 | 0.110 |
Why?
|
| Swine, Miniature | 1 | 2013 | 51 | 0.110 |
Why?
|
| Internship and Residency | 2 | 2020 | 1011 | 0.110 |
Why?
|
| Sus scrofa | 1 | 2013 | 45 | 0.110 |
Why?
|
| Cell Separation | 1 | 2013 | 196 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2583 | 0.110 |
Why?
|
| Adolescent | 3 | 2021 | 8959 | 0.110 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 81 | 0.110 |
Why?
|
| Device Removal | 2 | 2013 | 161 | 0.110 |
Why?
|
| Epidermis | 1 | 2013 | 101 | 0.110 |
Why?
|
| Cell Communication | 1 | 2013 | 195 | 0.110 |
Why?
|
| Surgicenters | 1 | 2011 | 5 | 0.100 |
Why?
|
| Mannose-Binding Lectins | 1 | 2011 | 6 | 0.100 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2011 | 23 | 0.100 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 61 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2013 | 459 | 0.100 |
Why?
|
| Swine | 1 | 2013 | 559 | 0.100 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 335 | 0.100 |
Why?
|
| Maxillofacial Injuries | 1 | 2011 | 4 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 882 | 0.100 |
Why?
|
| Skull Fractures | 1 | 2011 | 24 | 0.100 |
Why?
|
| Receptors, IgG | 1 | 2011 | 52 | 0.100 |
Why?
|
| Lectins, C-Type | 1 | 2011 | 85 | 0.100 |
Why?
|
| Rejuvenation | 1 | 2010 | 18 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 129 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 929 | 0.090 |
Why?
|
| Regenerative Medicine | 1 | 2010 | 24 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 173 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 996 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 61 | 0.090 |
Why?
|
| Monocytes | 1 | 2011 | 216 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 288 | 0.090 |
Why?
|
| Adipogenesis | 1 | 2009 | 37 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2011 | 280 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 378 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 2240 | 0.080 |
Why?
|
| Regeneration | 1 | 2010 | 147 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 188 | 0.080 |
Why?
|
| Cell Survival | 1 | 2011 | 972 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 264 | 0.080 |
Why?
|
| Islets of Langerhans | 1 | 2012 | 542 | 0.080 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 991 | 0.080 |
Why?
|
| Mutation | 1 | 2019 | 3978 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2011 | 666 | 0.080 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 235 | 0.080 |
Why?
|
| Interferon-gamma | 1 | 2010 | 445 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 1928 | 0.080 |
Why?
|
| Glucose | 1 | 2010 | 624 | 0.080 |
Why?
|
| Stem Cells | 1 | 2009 | 358 | 0.070 |
Why?
|
| Biomarkers | 1 | 2013 | 1697 | 0.070 |
Why?
|
| Phenotype | 1 | 2013 | 2389 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2010 | 930 | 0.070 |
Why?
|
| Animals | 3 | 2014 | 26650 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2022 | 80 | 0.050 |
Why?
|
| Ribs | 1 | 2022 | 45 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1202 | 0.050 |
Why?
|
| Prognosis | 2 | 2019 | 3639 | 0.050 |
Why?
|
| Buttocks | 1 | 2021 | 10 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 330 | 0.050 |
Why?
|
| Survivorship | 1 | 2020 | 18 | 0.050 |
Why?
|
| Elasticity | 1 | 2019 | 94 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 153 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2020 | 85 | 0.040 |
Why?
|
| Gene Expression | 2 | 2013 | 1286 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 158 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 298 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 148 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2019 | 456 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 200 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1598 | 0.040 |
Why?
|
| United States | 2 | 2021 | 6581 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 65 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 787 | 0.030 |
Why?
|
| Ventilator Weaning | 1 | 2014 | 24 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 468 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2013 | 69 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 315 | 0.030 |
Why?
|
| Child | 2 | 2015 | 6930 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 850 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2013 | 60 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1696 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 124 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 180 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2012 | 103 | 0.030 |
Why?
|
| Capital Financing | 1 | 2011 | 4 | 0.030 |
Why?
|
| Facility Design and Construction | 1 | 2011 | 4 | 0.030 |
Why?
|
| Fees, Medical | 1 | 2011 | 10 | 0.030 |
Why?
|
| Group Practice | 1 | 2011 | 7 | 0.030 |
Why?
|
| Wisconsin | 1 | 2011 | 39 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2500 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 1543 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2011 | 42 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 704 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2014 | 374 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1179 | 0.020 |
Why?
|
| Veins | 1 | 2010 | 93 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 212 | 0.020 |
Why?
|
| Arteries | 1 | 2010 | 175 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 780 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 2381 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5249 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 3050 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 3612 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1388 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 2433 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 1218 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 3997 | 0.010 |
Why?
|